Top Tech Companies (33)
Halaxy makes healthcare better all over the world. Halaxy is a platform for patients, practitioners and people everywhere, and provides: 1. Practice management software (EMR, billing and scheduling) for any practitioner of any profession in any practice anywhere in the world; 2. Searchable practitioner directories covering 50% of the English speaking world enabling people to find the right practitioner for...
We’re Medmate. Nice to meet you. We take the inconvenience and awkwardness out of pharmacy visits. Book a consultation with a doctor or get a script all online. It's fast, easy and convenient. Medmate was developed by doctors and pharmacists and born out of a desire to take the burden out of pharmacy shopping and make life that little bit...
The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly...
Seer is a medical technology company on a mission to give people more control of their most valuable assets—their health and their time—by reimagining how and where they undergo long-term clinical monitoring. Seer's products and services are focused on solving the problems related to the early and accurate diagnosis of epilepsy. Seer’s flagship suite of technologies, offered through a provider...
Lenexa Medical is an Australian-based MedTech company that has developed the LenexaCARE technology to empower clinicians to deliver targeted, long-term solutions for personalised pressure injury prevention and patient monitoring. Pressure injuries are mostly preventable, however affect millions of people globally each year whilst costing healthcare systems billions of dollars worldwide. In 2020, Australian public hospitals spent over $9 billion to...
Advancing the world’s transition to AI-supported healthcare.
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New...
Smileyscope is a multi-award winning digital therapeutics company with proprietary technology that reframes medical procedures using choreographed virtual-reality (VR) experiences to help reduce patient pain and anxiety, and improve the overall patient experience. Our vision is to expand the frontiers of patient-centered care, improving the moments that matter most. Smileyscope VR is the first regulatory body approved VR product for...
Welcome to Cabrini Health Cabrini is owned and operated by the Missionary Sisters of the Sacred Heart of Jesus who came to Australia in 1948 to take over the management of a 45-bed community hospital named St Benedict’s. Cabrini now has more than 800 beds and a comprehensive range of health services. There are acute facilities at Malvern and Brighton. The...
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced...
